• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Endo Pharmaceuticals Reports Strong First Quarter 2011 Financial Results


News provided by

Endo Pharmaceuticals

Apr 28, 2011, 04:05 ET

Share this article

Share this article


CHADDS FORD, Pa., April 28, 2011 /PRNewswire/ --

  • Total quarterly revenues increase 54 percent versus prior year;
  • Reported quarterly diluted EPS of $0.46, versus $0.51 for prior year
  • Adjusted diluted EPS of $1.00 reflecting growth of 35 percent from 2010

Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the first quarter 2011.

Total revenues during the first quarter of 2011 increased 54 percent to $560 million, compared with $364 million in the same quarter of 2010.  Net income for the three months ended March 31, 2011 was $56 million, compared with $60 million in the comparable 2010 period.  As detailed in the supplemental financial information below, adjusted net income for the three months ended March 31, 2011, was $120 million, compared with $87 million in the same period in 2010.  Reported diluted earnings per share for the quarter ended March 31, 2011 were $0.46 compared with $0.51 in the first quarter of 2010. Adjusted diluted earnings per share for the same period were $1.00 compared with $0.74 reported in 2010.


($ in thousands, except per share amounts)





Three months Ended March 31,



2011

2010

Change

Total Revenues

$  560,026

$  364,412

54%

Reported Net Income

55,787

60,355

(8)%

Reported Diluted EPS

$  0.46

$  0.51

(10)%

Adjusted Net Income

120,178

87,182

38%

Adjusted Diluted EPS

$  1.00

$  0.74

35%


"Endo had a terrific first quarter, with strong performance across every segment of our business," said Dave Holveck, president and CEO of Endo. "We continue our focus on creating sustainable long-term growth and look forward to delivering a strong performance in 2011."

First quarter 2011 Financial Results

The first quarter benefitted from very good contributions across our business. Branded and non-promoted drug sales rose 11 percent year-over-year, reflecting strong growth by key products in pain, urology and oncology. Revenues from our generics business, which benefit from the acquisition of Qualitest Pharmaceuticals, increased 419 percent. The first quarter also benefits year-over-year from the performance of the devices and services of our HealthTronics urology business, continued discipline in our investments in R&D and SG&A, as well as a lower effective tax rate, driven in part by the renewal of the R&D tax credit in the US.

2011 Financial Guidance

Endo reiterated its standalone 2011 revenue guidance of between $2.35 to $2.45 billion and full year adjusted diluted earnings per share of between $4.20 to $4.30 per share.  Endo now estimates reported (GAAP) diluted earnings per share to be between $2.25 and $2.35 per share.

Selected Operating Highlights

Acquisition of American Medical Systems (AMS)

On April 11, 2011, Endo Pharmaceuticals announced the that the company entered into a definitive agreement under which Endo will acquire AMS, a leading provider of world-class devices and therapies for male and female pelvic health, for $30 per share or $2.9 billion in cash, which includes the assumption and repayment of $312 million of AMS debt.

Endo believes that this acquisition will bring scale in its device and services business segment, and the combination of AMS with Endo's existing drug, device and services platform will provide additional cost-effective solutions across the entire urology spectrum.  In addition, the acquisition will further Endo's diversification and increase revenue, earnings and cash flow streams.

The transaction is subject to approval by AMS stockholders and clearance by the relevant antitrust authorities, and is expected to close late in the third quarter of 2011.

Launch of FORTESTA™ Gel

On March 3, 2011, Endo Pharmaceuticals announced that FORTESTA Gel for the treatment of low testosterone, or 'Low T' in adult males – is available by prescription in pharmacies across the country.  The clear, colorless and odorless gel comes in a small (60 gram) canister with a pump that delivers 10mg of testosterone with each actuation (pump).  FORTESTA Gel is applied once-a-day with one finger directly to the front and inner thighs – not to the upper body.

The introduction of FORTESTA Gel in the U.S. comes at a time when only about 1.3 million (9 percent) of the estimated 14 million men with Low T are actually receiving treatment.

Approval of Two Generic Products

On March 4, 2011, Qualitest Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Emoquette™ (Desogestrel and Ethinyl Estradiol Tablets 0.15mg/0.003mg, generic Ortho-Cept®) for the prevention of pregnancy in women who elect to use oral contraceptives for the prevention of pregnancy.

On March 24, 2011, Qualitest Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Toresmide tablets (generic Demadex® in 5 mg, 10 mg, 20 mg and 100 mg strengths).  Toresmide tablets are indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease, and for the treatment of hypertension alone or in combination with other antihypertensive agents.

Selected Product Review

PAIN PRODUCTS

LIDODERM®:  For the quarter ended March 31, 2011, net sales of LIDODERM increased 4 percent to $190 million, compared with $183 million in the same period a year ago.

OPANA® ER:  For the quarter ended March 31, 2011, net sales of OPANA ER increased 70 percent to $85 million, compared with $50 million in the same period a year ago.

Voltaren® Gel: First quarter 2011 net sales of Voltaren Gel increased 54 percent to $31 million, compared with $20 million for the same period in 2010.

FROVA®: Net sales of FROVA were $13 million for the three months ended March 31, 2011, compared with $15 million for the same period in 2010.

PERCOCET®: Net sales of PERCOCET were $27 million for the three months ended March 31, 2011, compared with net sales of PERCOCET in the same period in 2010 of $29 million.  

ONCOLOGY/ENDOCRINOLOGY PRODUCTS

SUPPRELIN® LA: Net sales of SUPPRELIN LA for the three months ended March 31, 2011 and 2010 were $11 million.

VANTAS®: Net sales of VANTAS for the three months ended March 31, 2011 and 2010 were $4 million.

VALSTAR™: Net sales of VALSTAR for the first quarter were $5 million compared with $4 million for the same period in 2010.  

OTHER BRANDED PRODUCTS

For the first quarter of 2011, net sales of other branded products were $10 million, compared with $23 million in the same period in 2010. To conform to current year presentation, net sales from our non-time released formulation of OPANA® have been reclassified and are now included within other branded product results. Additionally, in accordance with its revenue recognition policy, Endo has deferred revenues associated with the stocking of FORTESTA™ Gel. Certain sales deductions associated with the stocking of FORTESTA Gel are included within other branded product results.

GENERIC PRODUCTS

For the first quarter of 2011, net sales from the company's generic products, which include a full period of Qualitest Pharmaceuticals results, were $134 million, compared with $26 million in the same period in 2010.

DEVICES AND SERVICES

On July 12, 2010, Endo Pharmaceuticals completed its merger with HealthTronics, as a result of which HealthTronics has been acquired by, and is a wholly owned subsidiary of, Endo. Revenues from the HealthTronics subsidiary for the first quarter of 2011 were $50 million.

Conference Call Information

Endo will conduct a conference call with financial analysts to discuss this news release today at 5:00 p.m. ET.  Investors and other interested parties may call 800-599-9829(domestic) or 617-847-8703 (international) and enter passcode 16767498.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from April 28 at 8:00 p.m. ET until 11:59 p.m. ET on May 12, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 44532597.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 11:59 p.m. ET on May 12, 2011.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

Supplemental Financial Information

The following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the three months ended March 31, 2011 and March 31, 2010(in thousands, except per share data):


Three Months Ended March 31, 2011 (unaudited)

Actual Reported

(GAAP)

Adjustments


Adjusted

REVENUES

$  560,026

$  —


$  560,026






COSTS AND EXPENSES:





 Cost of revenues

231,558

(50,997)

(1)

180,561

 Selling, general and administrative

159,386

(3,462)

(2)

155,924

 Research and development

42,130

(11,001)

(3)

31,129

 Acquisition-related items

6,073

(6,073)

(4)

—






OPERATING INCOME

$  120,879

$  71,533


$  192,412






INTEREST EXPENSE, NET

18,790

(4,541)

(5)

14,249

OTHER EXPENSE, NET

348

—


348






INCOME BEFORE INCOME TAXES

$  101,741

$  76,074


$  177,815






INCOME TAXES

33,446

11,683

(6)

45,129






CONSOLIDATED NET INCOME

$  68,295

$  64,391


$  132,686






 Less: Net income attributable to noncontrolling interests

(12,508)

—


(12,508)






NET INCOME ATTRIBUTABLE TO ENDO PHARMACEUTICALS HOLDINGS INC.

$  55,787

64,391


$  120,178











DILUTED EARNINGS PER SHARE

$  0.46



$  1.00

DILUTED WEIGHTED AVERAGE SHARES

120,761



120,761


Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:


(1) To exclude amortization of commercial intangible assets related to marketed products of $37,211 and the impact of inventory step-up recorded as part of acquisition accounting of $13,786.

(2) To exclude certain start-up costs and separation benefits incurred in connection with continued efforts to enhance the company's operations.

(3) To exclude milestone and upfront payments to partners.

(4) To exclude acquisition-related costs of $6,758 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus and Qualitest acquisitions of ($685).

(5) To exclude additional interest expense as a result of adopting ASC 470-20.

(6) To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates.


Three Months Ended March 31, 2010 (unaudited)

Actual Reported

(GAAP)

Adjustments


Adjusted

REVENUES

$  364,412

$  —


$  364,412






COSTS AND EXPENSES:





 Cost of revenues

94,073

(17,217)

(1)

76,856

 Selling, general and administrative

133,335

(5,002)

(2)

128,333

 Research and development

29,168

(3,492)

(3)

25,676

 Acquisition-related items

1,529

(1,529)

(4)

—






OPERATING INCOME

$  106,307

$  27,240


$  133,547






INTEREST EXPENSE, NET

9,804

(4,050)

(5)

5,754

OTHER EXPENSE, NET

(219)

(204)

(6)

(423)






INCOME BEFORE INCOME TAXES

$  96,722

$  31,494


$  128,216






INCOME TAXES

36,367

4,667

(7)

41,034






NET INCOME ATTRIBUTABLE TO ENDO PHARMACEUTICALS HOLDINGS INC.

$  60,355

$  26,827


$  87,182











DILUTED EARNINGS PER SHARE

$  0.51



$  0.74

DILUTED WEIGHTED AVERAGE SHARES

118,031



118,031


Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:


(1) To exclude amortization of commercial intangible assets related to marketed products.

(2) To exclude certain costs incurred with connection with continued efforts to enhance the Company's operations.

(3) To exclude a milestone-like payment to a partner of $3,000 and certain costs incurred in connection with continued efforts to enhance the cost structure of the Company of $492.

(4) To exclude Indevus transaction and separation costs of $639 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of $890.

(5) To exclude additional interest expense as a result of adopting ASC 470-20 of $4,144 and to exclude amortization of the premium on debt acquired from Indevus of ($94).

(6) To exclude changes in fair value of financial instruments, net.

(7) To reflect the cash tax savings resulting from the Indevus acquisition and the tax effect of the pre-tax adjustments above at applicable tax rates.  



For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission.


Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for 2011








Year Ending



December 31, 2011







Projected GAAP diluted income per common share

$2.25

To

$2.35


Upfront and milestone-related payments to partners

$0.35


$0.35


Amortization of commercial intangible assets and inventory step-up

$1.35


$1.35


Acquisition and integration costs related to recent acquisitions.

$0.35


$0.35


Interest expense adjustment for ASC 470-20 and the amortization of the premium on debt acquired from Indevus

$0.16


$0.16


Tax effect of pre-tax adjustments at the applicable tax rates and certain other expected cash tax savings as a result of recent acquisitions

($0.26)


($0.26)


Diluted adjusted income per common share guidance

$4.20

To

$4.30







The company's guidance is being issued based on certain assumptions including:

  • Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results.
  • Includes all completed business development transactions as of April 28, 2011.
  • Includes certain expenses associated with the acquisition of American Medical Systems, Inc.  

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit www.endo.com.

(Tables Attached)

The following tables present Endo's unaudited Total Revenues for the three months ended March 31, 2011 and March 31, 2010:

Endo Pharmaceuticals Holdings Inc.

Total Revenues (unaudited)

(in thousands)



Three Months Ended

March 31,



2011

2010

Growth





LIDODERM®

$  189,725

$  182,607

4%

OPANA® ER

84,615

49,766

70%

PERCOCET®

26,960

28,673

(6)%

Voltaren® Gel

31,298

20,362

54%

FROVA®

13,208

15,082

(12)%

SUPPRELIN® LA

11,222

10,587

6%

VANTAS®

3,545

4,389

(19)%

VALSTAR™

4,801

3,750

28%

Other Brands

10,140

23,320

(57)%





Total Branded and Non-Promoted

$     375,514

$     338,536

11%





Total Generics

$  134,409

$  25,876

419%





Total Devices and Services

$  50,103

$  —

NM









 Total Revenues

$  560,026

$  364,412

54%






The following table presents unaudited condensed consolidated Balance Sheet data at March 31, 2011 and December 31, 2010:






March 31,

2011

December 31,

2010

ASSETS



CURRENT ASSETS:



Cash and cash equivalents

$  565,162

$  466,214

Accounts receivable, net

549,281

547,807

Inventories, net

205,296

178,805

Other assets

178,435

166,708




Total current assets

$  1,498,174

$  1,359,534




PROPERTY, PLANT AND EQUIPMENT, NET

213,452

215,295

GOODWILL

719,300

715,005

OTHER INTANGIBLES, NET

1,486,199

1,531,760

OTHER ASSETS

88,970

90,795




TOTAL ASSETS

$  4,006,095

$  3,912,389




LIABILITIES AND STOCKHOLDERS' EQUITY



CURRENT LIABILITIES:



Current liabilities

$  788,092

$  735,828




Total current liabilities

$  788,092

$  735,828




ACQUISITION-RELATED CONTINGENT CONSIDERATION

3,510

16,050

LONG-TERM DEBT, LESS CURRENT PORTION, NET

1,044,120

1,045,801

OTHER LIABILITIES

306,650

311,381




STOCKHOLDERS' EQUITY:



Total Endo Pharmaceuticals Holdings Inc. stockholders' equity

$  1,802,365

1,741,591




Noncontrolling interests

61,358

61,738




Total stockholders' equity

$  1,863,723

1,803,329




TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$  4,006,095

$  3,912,389





The following table presents unaudited condensed consolidated statement of cash flow data for the three months ended March 31, 2011 and 2010:



Three Months Ended
March 31,


2011

2010

OPERATING ACTIVITIES:



Consolidated net income

$  68,295

$  60,355

Adjustments to reconcile consolidated net income to net cash provided by operating activities:



Depreciation and amortization

47,741

21,521

Stock-based compensation

7,416

3,791

Amortization of debt issuance costs and premium / discount

5,997

5,657

Other

(1,284)

6,641

Changes in assets and liabilities which provided cash:

2,893

11,440




Net cash provided by operating activities

131,058

109,405




INVESTING ACTIVITIES:



Purchases of property, plant and equipment, net

(12,561)

(3,165)

Acquisition, net of cash acquired

—

—

Other

(710)

32,475




Net cash provided by (used in) investing activities

(13,271)

29,310




FINANCING ACTIVITIES:



Principal payments on debt, net of proceeds

(4,197)

—

Purchase of common stock

(17,552)

(29,008)

Other

2,910

1,803




Net cash used in financing activities

(18,839)

(27,205)




NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

98,948

111,510

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

466,214

708,462




CASH AND CASH EQUIVALENTS, END OF PERIOD

$  565,162

$  819,972





Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission.

SOURCE Endo Pharmaceuticals

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.